• NIA Innovations & COVID-19
  • Newsletter Sign-Up
  • FAQs
  • Case Studies
  • Contact Us
NIANIANIANIA
  • About
    • What the NIA offers
    • Selection Process
    • Core Team
    • Mentors
    • Partners
    • Collaborate
    • Apply
  • Fellows and Innovations
    • Overview
    • Fellows
    • Innovations
    • Alumni
  • Latest
    • Events
    • News & blogs

QbTest

    Home Innovations QbTest
    NextPrevious

    QbTest

    5th March 2020
    0

    A test using objective measures to speed up ADHD diagnosis and improve treatment evaluation

    QbTest is a CE-marked, FDA approved medical device that simultaneously measures attention, impulsivity and motor activity, a core requirement of the diagnostic criteria for ADHD. The individual patient’s performance is compared to an age and sex-matched control group in a clear visual report which aids diagnosis and treatment evaluation.

    “For me, the QbTest was a really big eye opener because now there wasn’t just someone looking at me and noticing my struggles, there was a scientific foundation to it. I finally felt like someone was listening to me.”

    Patient

    “QbTest has finally provided us an evidence-based tool adding objecting measurement to ADHD assessment.”

    Clinician

    The challenge 

    Undiagnosed and/or untreated ADHD can have significant negative effects on the person’s academic performance and family interactions, and dramatically increases the likelihood of anxiety disorders, eating disorders, psychosis, and depression. Early diagnosis and timely interventions reduce such risks, yet in the UK the average delay from first clinic visit to diagnosis is 18 months, the worst in Europe.

     

    The solution

    The objective data from QbTest helps clinicians to rule out or diagnose ADHD more efficiently. Most patients receive a decision at their first appointment rather than making 2 or 3 visits over a prolonged period as per the current approach to diagnosis. ADHD clinics benefit from a 20% increase in capacity and greater confidence in decision making.

     

    Impact*

    • Time from assessment to diagnosis reduced by 153 days
    • Released 20% clinical workforce time
    • 85% of patients found the QbTest results helpful
    • 94% of clinicians reported greater understanding of patients’ symptoms
    • Return on Investment per clinic of £84K per annum

    *Evaluation by EMAHSN from 3 NHS Trusts over 12 months

    Fellow: Tony Doyle

    Category:
    2020
    Tags:
    Early diagnosis and prevention
    Avatar

    Morgan McKean

    More posts by Morgan McKean

    Related Projects:

    Safe Steps

    early diagnosis and prevention

    View more

    Safe Steps

    early diagnosis and prevention

    Safe Steps

    early diagnosis and prevention

    Safe Steps
    2020-03-05

    Locum’s Nest

    workforce support and process improvement

    View more

    Locum’s Nest

    workforce support and process improvement

    Locum’s Nest

    workforce support and process improvement

    Locum’s Nest
    2020-03-05

    QbTest

    early diagnosis and prevention

    View more

    QbTest

    early diagnosis and prevention

    QbTest

    early diagnosis and prevention

    QbTest
    2020-03-05

    MediShout

    hospital-based care

    View more

    MediShout

    hospital-based care

    MediShout

    hospital-based care

    MediShout
    2020-03-05

    RIX Wiki

    integrated community-based care

    View more

    RIX Wiki

    integrated community-based care

    RIX Wiki

    integrated community-based care

    RIX Wiki
    2020-03-05

    HN

    integrated community-based care

    View more

    HN

    integrated community-based care

    HN

    integrated community-based care

    HN
    2020-03-05

    The WaterDrop

    hospital-based care

    View more

    The WaterDrop

    hospital-based care

    The WaterDrop

    hospital-based care

    The WaterDrop
    2020-03-05

    Patient Experience Platform (PEP)

    View more

    Patient Experience Platform (PEP)

    Patient Experience Platform (PEP)

    Patient Experience Platform (PEP)
    2020-03-05

    Contact Us
    nia@uclpartners.com
    @NHSAccelerator
    Newsletter Sign-Up
    Terms and Conditions | Privacy and Cookies
    NHS Innovation Accerlator
    Copyright 2017 NHS Innovation Accelerator
    • Menu
      • Latest
      • Case Studies
      • News and Events
      • Press and Media
      • FAQs (OLD)
      • Contact Us
    • Apply
    • Fellows and Innovations
      • Fellows
      • Innovations
    • Collaborate
    • Accelerator
      • Partners
      • What the NIA offers
      • Selection Process
      • Mentors
    NIA